In last trading session, EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) saw 0.65 million shares changing hands with its beta currently measuring 1.39. Company’s recent per share price level of $6.15 trading at -$0.2 or -3.15% at ring of the bell on the day assigns it a market valuation of $419.74M. That closing price of EYPT’s stock is at a discount of -376.59% from its 52-week high price of $29.31 and is indicating a premium of 4.07% from its 52-week low price of $5.90.
For EyePoint Pharmaceuticals Inc (EYPT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.08. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.48 in the current quarter.
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) trade information
Upright in the red during last session for losing -3.15%, in the last five days EYPT remained trading in the red while hitting it’s week-highest on Tuesday, 02/18/25 when the stock touched $6.15 price level, adding 18.97% to its value on the day. EyePoint Pharmaceuticals Inc’s shares saw a change of -17.45% in year-to-date performance and have moved -2.54% in past 5-day. EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) showed a performance of -29.47% in past 30-days.
Wall Street analysts have assigned a consensus price target of 22 to the stock, which implies a rise of 72.05% to its current value. Analysts have been projecting 22 as a low price target for the stock while placing it at a high target of 22. It follows that stock’s current price would drop -257.72% in reaching the projected high whereas dropping to the targeted low would mean a loss of -257.72% for stock’s current value.
EyePoint Pharmaceuticals Inc (EYPT) estimates and forecasts
This year revenue growth is estimated to fall -7.55% from the last financial year’s standing.
12 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 11.02M for the same. And 7 analysts are in estimates of company making revenue of 7.05M in the next quarter. Company posted 14.03M and 11.68M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 29.57% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -19.37% while estimates for its earnings growth in next 5 years are of -15.63%.
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT)’s Major holders
CORMORANT ASSET MANAGEMENT, LP is the top institutional holder at EYPT for having 8.32 million shares of worth $72.43 million. And as of 2024-06-30, it was holding 15.6467 of the company’s outstanding shares.
The second largest institutional holder is SUVRETTA CAPITAL MANAGEMENT, LLC, which was holding about 5.18 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.7279 of outstanding shares, having a total worth of $45.03 million.
On the other hand, Federated Hermes Kaufmann Fund and Federated Hermes Kaufmann Small Cap Fund are the top two Mutual Funds which own company’s shares. As of Oct 31, 2024 , the former fund manager was holding 2.04 shares of worth $12.54 million or 2.99% of the total outstanding shares. The later fund manager was in possession of 1.61 shares on Oct 31, 2024 , making its stake of worth around $9.91 million in the company or a holder of 2.36% of company’s stock.
